1. When Paying Attention Pays Back: Missense Mutation c.1006G>A p. (Val336Ile) in PRKAG2 Gene Causing Left Ventricular Hypertrophy and Conduction Abnormalities in a Caucasian Patient: Case Report and Literature Review
- Author
-
Emanuele Micaglio, Lara Tondi, Sara Benedetti, Maria Alessandra Schiavo, Antonia Camporeale, Giandomenico Disabato, Andrea Attanasio, Gianluigi Guida, Gianpaolo Carrafiello, Massimo Piepoli, Pietro Spagnolo, Carlo Pappone, and Massimo Lombardi
- Subjects
left ventricular hypertrophy ,hypertrophic cardiomyopathy ,PRKAG2 cardiomyopathy ,cardiac magnetic resonance ,genetic test ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
PRKAG2 cardiomyopathy is a rare genetic disorder that manifests early in life with an autosomal dominant inheritance pattern. It harbors left ventricular hypertrophy (LVH), ventricular pre-excitation and progressively worsening conduction system defects. Its estimated prevalence among patients with LVH ranges from 0.23 to about 1%, but it is likely an underdiagnosed condition. We report the association of the PRKAG2 missense variant c.1006G>A p. (Val336Ile) with LVH, conduction abnormalities (short PR interval and incomplete right bundle branch bock) and early-onset arterial hypertension (AH) in a 44-year-old Caucasian patient. While cardiac magnetic resonance (CMR) showed a mild hypertrophic phenotype with maximal wall thickness of 17 mm in absence of tissue alterations, the electric phenotype was relevant including brady–tachy syndrome and recurrent syncope. The same variant has been detected in the patient’s sister and daughter, with LVH + early-onset AH and electrocardiographic (ECG) alterations + lipothymic episodes, respectively. Paying close attention to the coexistence of LVH and ECG alterations in the proband has been helpful in directing genetic tests to exclude primary cardiomyopathy. Hence, identifying the genetic basis in the patient allowed for familial screening as well as a proper follow-up and therapeutic management of the affected members. A review of the PRKAG2 cardiomyopathy literature is provided alongside the case report.
- Published
- 2024
- Full Text
- View/download PDF